Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Substrate recognition and catalysis by UCH-L1.

Sarah J Luchansky1, Peter T Lansbury, Ross L Stein

  • 1Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital and Laboratory for Drug Discovery in Neurodegeneration, Harvard Center for Neurodegeneration and Repair, Cambridge, Massachusetts 02139, USA. sarah.luchansky@gmail.com

Biochemistry
|December 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kinetic and Mechanistic Studies of Human Oligoadenylate Synthetase 1.

Biochemistry·2024
Same author

Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer.

Molecular cancer therapeutics·2024
Same author

Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice.

Molecular neurodegeneration·2022
Same author

Kinetic and Mechanistic Studies of the Terminal Uridylyltransferase, Zcchc11 (TUT4).

Biochemistry·2022
Same author

Mechanisms of macromolecular reactions.

History and philosophy of the life sciences·2022
Same author

Kinetic Studies of the Activation of <i>Bordetella pertussis</i> Adenylate Cyclase by Calmodulin.

Biochemistry·2022

Researchers explored how Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) recognizes its ubiquitin substrate. Key ubiquitin residues were identified, revealing differences between UCH-L1 and UCH-L3 enzyme specificity for potential disease-targeted drug design.

Area of Science:

  • Biochemistry
  • Enzymology
  • Molecular Biology

Background:

  • Deubiquitinating enzymes are crucial for cellular processes, with their malfunction linked to diseases.
  • Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is associated with Parkinson's disease and cancer, but its cellular function is unclear.
  • Small molecule modulators are being developed to study UCH-L1's cellular roles.

Purpose of the Study:

  • To investigate the substrate recognition mechanism of UCH-L1.
  • To identify specific ubiquitin residues involved in UCH-L1 binding and catalysis.
  • To compare the substrate specificity of UCH-L1 with its homologue, UCH-L3.

Main Methods:

  • Development of a panel of ubiquitin fusion proteins to probe enzyme-substrate interactions.

Related Experiment Videos

  • Determination of activation parameters for selected ubiquitin variants.
  • Comparative analysis of UCH-L1 and UCH-L3 binding and catalytic mechanisms.

    • Main Results:

    • Identification of critical ubiquitin side chains essential for forming the Michaelis complex and catalysis.
    • Elucidation of distinct substrate recognition features between UCH-L1 and UCH-L3.
    • Demonstration of significant differences in substrate specificity between the two enzymes.

    Conclusions:

    • Specific ubiquitin residues are vital for UCH-L1's enzymatic activity.
    • UCH-L1 and UCH-L3 exhibit differential substrate specificities, offering opportunities for selective inhibitor design.
    • Understanding these mechanistic differences can inform therapeutic strategies for UCH-L1-associated diseases.